Click to view the original PDF
Caixin securities issued a research report on August 13, maintaining the Bloomage Biotechnology Corporation Limited(688363) recommended rating, with a target price range of 285.8 ~ 330.4 yuan. As of the reporting date, the latest closing price of the company was 210 yuan, with 36.1% ~ 57.33% upward space compared with the target price. Caixin securities predicts that Bloomage Biotechnology Corporation Limited(688363) 2021's net profit attributable to the parent company will be 914 million yuan, with a year-on-year increase of 41.52%.
Main financial indicators and valuation
2021E
2022E
2023E
Total operating revenue (RMB 100 million) 434761 nine thousand three hundred and eighty-three point one four
Net profit attributable to parent company (RMB 100 million) 9141.2 million two hundred and sixteen point one nine
Earnings per share (yuan) 1.92 fifty-three point three seven
Net assets per share (yuan) 11.9813 eight hundred and sixteen point three
Price earnings ratio (PE) 110.9684 three thousand seven hundred and sixty-two point six five
Price to book ratio (PB) 17.6415 three thousand one hundred and twelve point nine six
Return on net assets (%) 15.918 one hundred and twenty point seven
Return on total assets (%) 14.216 two hundred and eighteen point three
Note: the data is obtained from the text of the research report.
Bloomage Biotechnology Corporation Limited(688363) four research reports of securities companies have been paid attention to in the past month, with an average target price of 304.05 yuan. The detailed data of the research report are shown in the table below:
Research report date
Organization abbreviation
Target price
This rating
details
On August 13, 2021, Caixin securities 285.8 - 330.4 recommended the Chinese craftsman to ride the wind and solidify the skin and jade muscle of the Xi Dynasty
August 3, 2021 Dongguan Securities - Recommended in-depth report: the layout of the whole industrial chain has made it a giant of hyaluronic acid
2021-07-26 China International Capital Corporation Limited(601995) 300 outperforms the industry four-wheel drive, and the industrial chain leader is moving towards a platform leader
2021-07-20 Sinolink Securities Co.Ltd(600109) - buy the four-wheel drive strategy and establish the layout of the whole hyaluronic acid industry chain
Disclaimer: This article is based on big data production and is for reference only. It does not constitute any investment suggestions. Therefore, the operator shall bear the operational risk.
